Option chain shows key data for Hercules Capital, Inc. 6.25% Notes due 2033's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Hercules Capital, Inc. 6.25% Notes due 2033.

Hercules Capital, Inc. 6.25% Notes due 2033 (NYSE:HCXY) Stock, Option Chain

Hercules Capital, Inc. 6.25% Notes due 2033

Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform
Built on Illumina's powerful sequencers, new, disruptive omics solutions surpass industry standards for quality, scale, accuracy, and replicability
SAN DIEGO, Feb. 24, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of omics solutions and sequencing applications. The solutions – spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software – will enable researchers to derive breakthrough insights around the drivers of disease. The new omics solutions surpass industry standards for scale, accuracy, and reliability because they are built on Illumina's powerful sequencers, known for unmatched quality, consistency, and accuracy. The expanded multiomics portfolio will be presented today at the Advances in Genome Biology and Technology (AGBT)&nbsp;General Meeting.

Biotech

News

General

ILMN

Illumina Unveils Largest Omics Solutions Portfolio Including Genomics, Spatial, Single Cell, CRISPR Technologies; Introduces Multimodal Data Analysis Platform

In the current market session, Enterprise Prods Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) share price is at $33.50, after a 0.48% spike. Moreover, over the past month, the stock fell by 1.10%, but in the past year, went up by 20.75%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1740406519_0.png" alt="Past Year Chart" />

<h3>Enterprise Prods Partners P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 29.51 in the Oil, Gas &amp; Consumable Fuels industry, Enterprise Prods Partners Inc. has a lower P/E ratio of 12.39. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1740406519_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into Enterprise Prods Partners Inc's Price Over Earnings

<a href="https://www.benzinga.com/startups/25/02/43451833/warren-buffetts-1m-bet-why-simple-index-funds-crushed-hedge-funds-by-7-1-to-2-2-over-a-decade">Warren Buffett's</a> Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>, BRK.B))&nbsp; made some big moves in the last quarter, shifting its investments in response to changing market conditions.&nbsp;
<a href="https://13f.info/13f/000095012325002701-berkshire-hathaway-inc-q4-2024">A regulatory filing</a> released on Feb. 14, showed that Berkshire slashed its stake in Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), cutting its shares from over 1 billion to about 680 million by the end of last year. The drop reduced Berkshire's ownership from over 13% to 11%, bringing the value of the investment from about $41 billion to under $30 billion.
Don't Miss:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
<h2 class="wp-block-heading">Strategic Portfolio Adjustments</h2>
Beyond Bank of America, Berkshire adjusted several other financial holdings. According to the filing, the firm sold 74% of its Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) stake, 18% of its Capital One (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) position, and 54% of its shares in Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>).&nbsp;
It also trimmed investments in Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), Louisiana-Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>), and T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>). The changes indicate a move away from financial stocks and select industries.
At the same time, Berkshire made a notable addition, buying a $1.2 billion stake in Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>), the company behind popular beers like Corona and Modelo. As per market trends, consumer staples tend to hold up well in uncertain economic times, making this a strategic shift toward more stable investments.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
Berkshire also increased its holdings in companies tied to steady consumer demand. Its stake in Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) grew by 86%, and its investment in Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) jumped by 48%.&nbsp;
These moves suggest confidence in businesses that remain relevant regardless of market conditions—whether people are tightening their budgets or not, they still order pizza and maintain their pools.
Not all holdings made the cut. Berkshire fully exited Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) despite only acquiring shares in the second quarter of 2024.&nbsp;
See Also: Many don&#8217;t know there are tax benefits when buying a unit as an investment —<a href="https://www.benzinga.com/money/casa-shares"> Here&#8217;s how to invest in real estate by mirroring BlackRock's big move</a>
It also sold off its positions in two major exchange-traded funds (ETFs) that track the S&amp;P 500—SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>). This suggests a more targeted approach rather than following the broader market.
Berkshire's cash pile has reached record levels. According to its <a href="https://www.berkshirehathaway.com/qtrly/3rdqtr24.pdf">financial reports</a>, the company sold about $133 billion worth of stocks in the first nine months of 2024 while buying less than $6 billion.&nbsp;
Share buybacks also slowed, with under $3 billion spent compared to nearly $70 billion over the previous four years, <a href="https://africa.businessinsider.com/news/warren-buffett-dumped-stocks-built-a-dollar300-billion-cash-pile-and-updated-his/pgecrnn">according to Business Insider</a>.&nbsp; These moves helped Berkshire's cash reserves soar past $300 billion for the first time, nearly doubling from $168 billion at the start of the year, the report added.&nbsp;
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

CHTR

POOL

TMUS

ULTA

Berkshire Hathaway Dumps Ulta Beauty, Citi, And ETFs – But Buffett Just Bet $1.2 Billion On This Alcohol Giant

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) has outperformed the market over the past 10 years by 5.34% on an annualized basis producing an average annual return of 16.35%. Currently, Autodesk has a market capitalization of $61.65 billion. 
Buying $1000 In ADSK: If an investor had bought $1000 of ADSK stock 10 years ago, it would be worth $4,453.12 today based on a price of $286.06 for ADSK at the time of writing.
<h3>Autodesk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740406509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ADSK

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

MSFT

Microsoft To Jefferies Says 'Strongly Refute' Any Change To Data Center Strategy

Barclays analyst John Coffey maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Overweight and lowers the price target from $120 to $117.

Price Target

Analyst Ratings

FOUR

Barclays Maintains Overweight on Shift4 Payments, Lowers Price Target to $117

WRAP

Wrap Technologies Has Completed The Acquisition Of W1 Global; Terms Not Disclosed

On Monday, Glaukos Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) received the &#8220;Day 74&#8221; notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-gen corneal cross-linking iLink therapy for keratoconus, a sight-threatening corneal disease, is sufficiently complete to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43908675/glaukos-announces-fda-acceptance-of-nda-submission-for-epioxa" rel="noreferrer noopener">permit a substantive review</a>.
The Prescription Drug User Fee Act goal date for the completion of the FDA&#8217;s review of the Epioxa NDA is set for Oct. 20, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43883818/glaukos-delivers-mixed-q4-results-analyst-sees-growing-investor-interest-during-transition" rel="noreferrer noopener">Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition</a>
&#8220;The acceptance of the Epioxa NDA represents another important step in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive corneal cross-linking drug therapy that does not require removal of the corneal epithelium, the outermost layer of the front of the eye,&#8221; said Glaukos CEO Thomas Burns.
The NDA submission includes data from two Phase 3 pivotal Epioxa trials, which achieved the pre-specified primary efficacy endpoints and demonstrated favorable tolerability and safety profiles.
Glaukos&#8217; corneal cross-linking iLink therapies use proprietary, bio-activated drug formulations designed to strengthen corneal tissue and halt the progression of keratoconus.
Glaukos&#8217; first-generation iLink therapy, known as Photrexa, or&nbsp;Epi-off, is the first and only FDA-approved therapy that has been shown to slow or halt disease progression.
Epioxa utilizes a proprietary, novel drug formulation designed to penetrate the epithelial layer of the cornea, a stronger UV-A irradiation protocol, and supplemental oxygen to enhance cross-linking.
Price Action: GKOS stock is up 25% at $157.36&nbsp;during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43890152/insulets-strong-q4-highlights-surging-omnipod-demand-and-growth-potential-analyst-sees-continued-growth-in-2025" target="_blank" rel="noreferrer noopener">Insulet&#8217;s Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst</a></li>
</ul>
Image: Shutterstock

Health Care

Movers

GKOS

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Barclays analyst Ramsey El-Assal maintains Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) with a Overweight and raises the price target from $28 to $29.

RELY

Barclays Maintains Overweight on Remitly Global, Raises Price Target to $29

WIIM

WLKP

Westlake Chemical Partners LP shares are trading higher after the company reported better-than-expected Q4 financial results.

Barclays analyst John Coffey maintains Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) with a Overweight and lowers the price target from $17 to $15.

Barclays Maintains Overweight on Nu Holdings, Lowers Price Target to $15

Barclays analyst Jiong Shao maintains NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) with a Equal-Weight and raises the price target from $82 to $104.

NTES

Barclays Maintains Equal-Weight on NetEase, Raises Price Target to $104

Earnings

ICCH

ICC Holdings FY24 EPS $0.54 Vs $0.96 YoY

Shares of aerospace manufacturer and launch service provider Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) are <a href="https://www.benzinga.com/premarket">trading higher in premarket</a> on Monday.
Rocket Lab National Security LLC, a wholly owned subsidiary of Rocket Lab USA, has reached a key milestone with the successful conclusion of the Critical Design Review (CDR) for the <a href="https://www.benzinga.com/pressreleases/25/02/b43910080/rocket-lab-clears-critical-design-review-for-space-force-victus-haze-mission">U.S. Space Force's Space Systems Command </a>(SSC) mission, VICTUS HAZE. 
The VICTUS HAZE mission, led by Space Safari and in collaboration with the Defense Innovation Unit (DIU), aims to quickly deploy a spacecraft capable of performing rendezvous and proximity operations. 
&#8220;The ability to build a spacecraft, launch it, and operate it all in-house, on a tactically responsive timeline, is incredibly rare, but with our extensive launch heritage and deep vertical integration across space systems, we&#8217;re ideally suited to make this mission a success,&#8221; said president and CEO of Rocket Lab National Security, Brad Clevenger.
Also Read: <a href="https://www.benzinga.com/25/02/43880110/james-bond-franchise-shifts-hands-to-amazon-mgm-studios">James Bond&#8217;s New Era: Amazon MGM Studios Takes Creative Reins of Franchise</a>
&#8220;VICTUS HAZE solidifies Rocket Lab as a trusted and highly capable, end-to-end space company that can enable complex missions to serve the needs of the nation,&#8221; Clevenger added.
This spacecraft is specifically designed to address space-based threats, ensuring launch readiness within 24 hours. Rocket Lab&#8217;s Pioneer spacecraft will be launched aboard the company&#8217;s Electron rocket from Launch Complex 1 in Mahia, New Zealand.
Following the successful CDR, the project advances into the production phase. During this phase, the spacecraft and launch vehicle will be integrated and preparations for the ground segment will begin.
The mission aims to showcase the capability to monitor and intercept objects in orbit, strengthening the U.S. Space Force&#8217;s capacity to rapidly address potential space threats.
Price Action: RKLB shares are trading higher by 0.72% at $23.72 in premarket at last check Monday.
Read Next: <a href="https://www.benzinga.com/25/02/43881721/coca-cola-warns-shortage-of-diverse-talent-could-harm-future-success">Coca-Cola Warns Shortage Of Diverse Talent Could Harm Business</a>
Photo: Shutterstock

RKLB

Rocket Lab Achieves Critical Design Review For US Space Force Mission

Barclays analyst Matthew Bouley maintains JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) with a Equal-Weight and lowers the price target from $9 to $6.

JELD

Barclays Maintains Equal-Weight on JELD-WEN Holding, Lowers Price Target to $6

SaverOne 2014 Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>), a transportation safety technology company, has been awarded its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43910063/saverone-granted-new-patent-in-the-united-states-further-expanding-its-ip-portfolio" rel="noreferrer noopener">13th patent</a> by the United States Patent and Trademark Office (USPTO). Issued on February 18, 2025, under patent number 12,231,899, the patent covers SaverOne&#8217;s system designed to restrict mobile phone use while driving.
This patented technology enhances SaverOne&#8217;s in-vehicle safety system by allowing drivers to access only approved applications, such as navigation or calls, while blocking all others. It achieves this through wireless communication between the vehicle&#8217;s Phone Location Unit and the driver&#8217;s mobile device.
Under U.S. law, the patent term is 20 years from the application&#8217;s effective filing date. With this new patent, SaverOne&#8217;s portfolio includes 23 patents, 13 of which have been granted in various jurisdictions and 10 more pending. 
SaverOne CEO Ori Gilboa emphasized that the latest U.S. patent grant further strengthens the company&#8217;s intellectual property portfolio, highlighting the uniqueness and innovation of its technology. He noted that as mobile phone-related distractions continue to pose a major risk to road safety, SaverOne remains dedicated to developing and protecting advanced solutions to help prevent accidents.
Recently, SaverOne&#8217;s U.S. distributor, Motor Supply, successfully completed a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43780269/saverone-announces-first-u-s-commercial-agreement-with-fedex-trucking-contractor-mdm-express" rel="noreferrer noopener">pilot with FedEx</a> contractor MDM Express, which led to a full fleet installation. This milestone strengthened SaverOne&#8217;s U.S. expansion and fleet safety impact.
Price Action: SVRE shares are trading higher by 4.62% at $4.31 premarket at the last check Monday.
Image via Shutterstock.

Equities

SVRE

SaverOne Expands IP Portfolio With New US Patent, Stock Gains

UNIT

Uniti Group shares are trading higher after Raymond James upgraded its stock rating from outperform to strong buy.

AREC

American Resources shares are trading higher after the company announced it has agreed to source commodities for refinement by ReElement Technologies.

Barclays analyst Matt Miksic maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Overweight and raises the price target from $100 to $103.

GMED

Barclays Maintains Overweight on Globus Medical, Raises Price Target to $103

Citizens Capital Markets analyst Patrick Walravens reiterates Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Market Outperform and maintains $450 price target.

Reiteration

Citizens Capital Markets Reiterates Market Outperform on Salesforce, Maintains $450 Price Target

Press Releases

Hercules Capital Announces Upcoming Event for the Financial Community

Hercules Capital Receives Reaffirmed Baa3 Investment Grade Rating with Revised Outlook to Positive from Moody's Investors Service

Hercules Capital Announces Date for Release of Third Quarter 2024 Financial Results and Conference Call

Hercules Capital Declares a Total Cash Distribution of $0.48 per Share for the Third Quarter 2024

Hercules Capital Reports Third Quarter 2024 Financial Results

Hercules Capital Renews and Increases Its Multi-Currency SMBC Credit Facility to $300.0 Million

Hercules Capital Announces Date for Release of Fourth Quarter and Full-Year 2024 Financial Results and Conference Call

Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Fourth Quarter 2024

Hercules Capital Announces New Supplemental Cash Distribution of $0.28 per Share

Hercules Capital Reports Fourth Quarter and Full-Year 2024 Financial Results

HCXY

HTGC

Comments

Hercules Capital, Inc. 6.25% Notes due 2033

Hercules Capital, Inc. 6.25% Notes due 2033 (HCXY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga